Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,019 | $1,486 | $1,346 | $3,047 |
| - Cash | $120 | $110 | $68 | $48 |
| + Debt | $88 | $85 | $17 | $18 |
| Enterprise Value | $2,987 | $1,461 | $1,295 | $3,017 |
| Revenue | $47 | $79 | $47 | $73 |
| % Growth | -40.1% | 67.8% | -35.7% | – |
| Gross Profit | $47 | $79 | $47 | $73 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$216 | -$143 | -$152 | -$98 |
| % Margin | -459.4% | -182.2% | -323.9% | -134.1% |
| Net Income | -$224 | -$147 | -$155 | -$100 |
| % Margin | -475.6% | -187% | -330.6% | -137.6% |
| EPS Diluted | -2.98 | -2.52 | -2.87 | -2.09 |
| % Growth | -18.3% | 12.2% | -37.3% | – |
| Operating Cash Flow | -$195 | -$103 | -$153 | -$129 |
| Capital Expenditures | -$13 | -$34 | -$3 | -$2 |
| Free Cash Flow | -$207 | -$137 | -$156 | -$131 |